Debut Plus

₹1,894.6

▼ -76.48 -3.88%

As of 23 Oct 2026 · delayed

NSE Listed · Pharmaceuticals

LT-ASM · ASM 1
What does LT-ASM · ASM 1 mean?
NSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-08-13

Beta Drugs Limited (BETA)

Volume: 1,55,586Avg Vol 1W: 1,58,617Avg Vol 1M: 69,54152W Range:₹990.1₹2,807.9
Market Cap₹2,100 Cr
Current Price₹1,894.6
Previous Close₹1,971.08
High / Low (52w)₹2,807.9 / ₹990.1
Volume1,55,586
Avg Vol (1W)1,58,617
Avg Vol (1M)69,541
Stock P/E40.46
Book Value₹394.8
Dividend Yield0%
ROE11.86%
ROA8.13%
Revenue (TTM)—
Revenue Growth22.54%
Profit Margin11.69%
Total Debt₹127 Cr
Shares Outstanding1 Cr
Face Value₹10
EPS (TTM)₹46.83
P/B4.8
Debt / Equity0.43
50 DMA₹2,107.66
200 DMA₹1,712.22
Day change-3.88%
SurveillanceLT-ASM · ASM 1
Price Chart
₹1,894.6▲ 2.91% · 1Y
₹2668₹10305.7L
2025-10-27
2026-10-23

20-day avg volume: 74K shares

Pros
  • Company is almost debt-free.
Quarterly Results
MetricDec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026Sept 2026
Revenue₹88 Cr₹94 Cr₹100 Cr₹103 Cr₹87 Cr₹94 Cr₹126 Cr₹137 Cr
EBITDA₹16 Cr₹18 Cr₹19 Cr₹20 Cr₹15 Cr₹16 Cr₹25 Cr₹27 Cr
Net Profit₹9 Cr₹9 Cr₹12 Cr₹12 Cr₹9 Cr₹9 Cr₹16 Cr₹19 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026Sept 2026
Revenue₹369 Cr₹66 Cr₹54 Cr₹50 Cr₹396 Cr₹54 Cr₹56 Cr₹58 Cr
EBITDA₹69 Cr₹8 Cr₹5 Cr₹7 Cr₹70 Cr₹10 Cr₹10 Cr₹6 Cr
Net Profit₹42 Cr₹4 Cr₹2 Cr₹3 Cr₹41 Cr₹5 Cr₹6 Cr₹4 Cr
EPS42.02———40.92———
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹83 Cr₹107 Cr₹118 Cr₹158 Cr₹198 Cr₹254 Cr₹436 Cr₹496 Cr
Total Liabilities₹42 Cr₹50 Cr₹49 Cr₹66 Cr₹76 Cr₹97 Cr₹239 Cr₹251 Cr
Equity₹41 Cr₹57 Cr₹69 Cr₹92 Cr₹123 Cr₹157 Cr₹197 Cr₹245 Cr
Total Debt————————
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹0 Cr₹8 Cr₹19 Cr₹30 Cr₹23 Cr₹31 Cr₹36 Cr₹37 Cr
Investing₹-21 Cr₹-15 Cr₹-6 Cr₹-22 Cr₹-19 Cr₹-14 Cr₹-36 Cr₹-51 Cr
Financing₹12 Cr₹9 Cr₹-8 Cr₹-1 Cr₹-2 Cr₹-7 Cr₹118 Cr₹-8 Cr
Free Cash Flow₹0 Cr₹8 Cr₹19 Cr₹30 Cr₹23 Cr₹31 Cr₹36 Cr₹37 Cr
Shareholding
Promoter 59.1% Institutions 7.26% Public 33.65%
Efficiency & Working Capital
ROCE16.8%
Interest Coverage9.2
Dividend Payout—
Debtor Days113 d
Inventory Days71 d
Payable Days76 d
Cash Conversion Cycle107 d
Working Capital Days184 d
Shareholding Details

As of 2026-06-30

Promoter59.1%
FII1%
DII6.2%
Institutions7.3%
Public33.6%
Promoter Pledge0%
No. of Shareholders7,359
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodNov 2024Nov 2024Dec 2024Mar 2025Jun 2025Sept 2025Nov 2025Nov 2025Dec 2025Mar 2026May 2026Jun 2026
Promoters66.7%66.7%66.7%66.7%66.7%66.7%66.7%66.7%64.9%66.7%59.1%59.1%
FIIs1.2%1.2%1.2%0.9%0.9%0.9%0.9%0.9%1.1%0.9%3%1%
DIIs0.2%0%0%0%0%0%0.3%0%1.9%0.3%6%6.2%
Public31.9%32.1%32.1%32.4%32.4%32.4%32.1%32.4%32.1%32.1%31.9%33.6%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders2,7932,7932,8823,0543,1393,1843,0033,0033,6943,1845,0277,359
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Neeraj BatraShareholding of Promoter and Promoter Group58.4%64,73,631
Suryavanshi Commotrade Private LimitedPublic Shareholding6.1%6,80,026
Ashish KacholiaPublic Shareholding4.9%5,43,800
Healthquad Trust IiPublic Shareholding4.1%4,53,696
Inti Capital Vcc - Inti Capital IPublic Shareholding1.9%2,11,691
Airavat Capital Trust - Airavat Capital Trust IiPublic Shareholding1.6%1,77,171
Bsas Infotech Limited .Public Shareholding1.2%1,32,762
Anjali Ajit DevalPublic Shareholding1.1%1,25,596
Rahul BatraShareholding of Promoter and Promoter Group0.4%41,632
Varun BatraShareholding of Promoter and Promoter Group0.3%34,891
Aditi BatraShareholding of Promoter and Promoter Group0%619
Heena BatraShareholding of Promoter and Promoter Group0%619
Board of Directors
NameDesignationYear
Rahul BatraChairman & Managing Director2025
Varun BatraJoint Managing Director2025
Balwant SinghWhole-time Director2025
Ashutosh ShuklaWhole-time Director2025
Ajay MahipalNon Executive Director2025
Rohit PartiIndependent Director2025
Manmohan KhannaIndependent Director2025
Sanjay SehgalIndependent Director2025
Lalit Kumar WattsIndependent Director2025
Monica JainIndependent Director2025
Rajni BrarCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Manufacturing of Oncology Medicines₹0 Cr—
Segments — Geography
RegionRevenueShare
Domestic Sales₹156 Cr71%
Export Sales₹64 Cr29%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹10111010
Corporate Actions
TypeDateValueRemark
forthcoming2026-07-20Board Meetings—
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202526004031
2025100001
202524004029
Company Information
Incorporated2005
ChairmanRahul Batra
AuditorKhurana Sharma & Co
Investor Email[email protected]
🌐 www.betadrugslimited.com ↗

📍 Village Nandpur, Baddi, Himachal Pradesh, 174101

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search